Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.

The KRD regimen showed borderline significance (median PFS: 13.54 vs 23.41 months, p = 0.049), while the trends in both E-IRD (median PFS: 13.41 vs 21.61 months, p = 0.441) and L-IRD (median PFS: 11.57 vs 9.18 months, p = 0.785) groups were insignificant, Fig. 3 .

also in 7,017 other papers

The International Staging System (ISS) at the time of MM progression showed a trend towards worse outcomes in advanced ISS groups, but the results were insignificant in all cohorts: DRD (median PFS: ISS 1—not reached vs ISS 2—20.69 vs ISS 3—16.07 months, p = 0.2), KRD (median PFS: ISS 1—17.25 vs ISS 2—13.77 vs ISS 3—16.52 months, p = 0.665), and E-IRD (median PFS: ISS 1—24.95 vs ISS 2—13.54 vs ISS 3—17.77 months, p = 0.166).

also in 53,322 other papers